SENSEX NIFTY

Mylan

Jan 18, 2017 at 20:48 | Source: PTI
The country "is one of the largest producers of pharmaceutical products and a leading player in the global generics market, exporting nearly 50 per cent of its production", according to the achievement report of the sector under the government's 'Make in India' initiative.
Jan 12, 2017 at 09:44 | Source: Moneycontrol.com
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Jan 12, 2017 at 08:56 | Source: PTI
The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.
Jan 12, 2017 at 08:43 | Source: CNBC-TV18
Following US president-elect Donald Trumps explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Jan 09, 2017 at 14:06 | Source: Moneycontrol.com
Portuguese drug regulator Infarmed issued observations on January 3 after it detected non-conformities in good manufacturing practices related to the granulation and primary packaging of tablets in batches of drugs related to paracetamol and metformin supplied to Mylan, Bluepharma and Sandoz.
Dec 27, 2016 at 15:41 | Source: Moneycontrol.com
This study was the last major step of a multiple-phased programme to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.
Nov 30, 2016 at 10:41 | Source: Moneycontrol.com
Lupin shares climbed nearly 2 percent intraday Wednesday after receiving approval from the US health regulator for Nuvigil tablets that improves wakefulness.
Nov 04, 2016 at 11:39 | Source: Moneycontrol.com
Pharma stocks, especially which have large exposure to United States, saw knee-jerk reaction on Friday after a media report indicated that US prosecutors are undertaking an investigation into the suspected price collusion.
Nov 04, 2016 at 09:54 | Source: PTI
Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients, who are often facing significant expense to manage their disease, Biocon said in a regulatory filing.
Messages on Mylan »

cpmc

Silver Member

35 Followers

Natco Pharma  

of the demonetisation and currency shortfall affecting retail trade off takes. My guess overall - Q3 shud be similar to Q2 or slightly better in overall earnings. Q4 shud be a blockbuster. Let`s see how it unfolds For the upcoming week - all eyes and ears will be on the Kothur FDA outcome and TAD update on Mylan`s g

12.13 PM Jan 21st

merp96

New Member

7 Followers

Natco Pharma  

tad is target action date for usfda approval. 28 jan 2017 is tad for 40mg copaxone for mylan. please read my litigation message.

3.21 PM Jan 19th

cpmc

Silver Member

35 Followers

Natco Pharma  

My understanding is that all the generic challengers for the 40 mg are basing an argument that the 40 mg just an increased strength and not a different formulation per se than the 20 mg (what Teva is claiming). That said Mylan needs to get an approval for the 20 mg which has taken a very long time

12.45 PM Jan 19th

merp96

New Member

7 Followers

Natco Pharma  

Teva has sued Mylan for alleged patent infringement over Copaxone (glatiramer acetate injection), a treatment for patients with relapsing-remitting forms of multiple sclerosis.The case, which was filed yesterday, January 17, at the US District Court for the Northern District of West Virginia

11.08 AM Jan 19th

abhicivil30
3

New Member

3 Followers

Biocon  

if MYLAN recovers in US markets today, BIOCON will shoot tomorrow.

4.24 PM Jan 17th

stock specific

Platinum Member

219 Followers

Biocon  

USFDA to review Biocon-Mylan`s biosimilar drug for breast cancer news may give the push for the biocon share price to 1025 Read more at:

11.56 PM Jan 11th

N2O

Platinum Member

211 Followers

Biocon  

Hopefully Biocon-Mylan will get USFDA approval for biosimilars for breast cancer

9.17 PM Jan 11th

BSE/NSE Announcer

Platinum Member

20404 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated January 11, 2017, titled "U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocons Proposed Biosimilar Trastuzumab".

6.32 PM Jan 11th

rjstocks99

New Member

0 Follower

Biocon  

The HERITAGE data was submitted by Mylan to the U.S. Food and Drug Administration (FDA) as part of the biologics license application (BLA) for MYL-1401O last month.

5.38 PM Dec 28th 2016

rjstocks99

New Member

0 Follower

Biocon  

The results confirm the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon, in comparison to branded trastuzumab, according to a company statement

5.33 PM Dec 28th 2016

News across the web »
Dec 30, 2016 at 22:45 | Source: FirstPost
Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.